Superworth

Matinas BioPharma price to sales ratio MTNB

Market value divided by revenue over the last twelve months, since 2018.

Today, Nov 2, 2026
n/m
not a meaningful number
Last meaningful
34.7×
Aug 2024
8-year median
22.8×
8-year range
8.8× to 194×
Peer median
0.7×

Matinas BioPharma's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2024, at 34.7×.

On the days it had one over the last 8 years, its median was 22.8×, from 8.8× in Sep 2023 to 194× in Sep 2018.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202434.7×19.7×53.8×
202321.8×8.8×25.2×
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
2019n/m a value too high to mean anything
2018184×162×194×

Against its peers

Companies in Drug Manufacturers - General nearest Matinas BioPharma's size, closest first, today.

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Matinas BioPharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.